Comparative activity of posaconazole and systemic azole agents against clinical isolates of filamentous fungi from a global surveillance programme.

Cecilia Godoy CarvalhaesPaul R RhombergMichael PfallerMariana Castanheira

Published in: JAC-antimicrobial resistance (2021)

Posaconazole and other mould-active azoles showed good activity against Aspergillus spp. causing IMI, but clinicians should be aware of regional rates of voriconazole-NS A. fumigatus.

Keyphrases

public health
palliative care
clinical trial